STXS
SinkerStereotaxis, Inc. · Healthcare · United States · $102M cap · $709K/day traded
$0.9 -12.6% · close 11 Nov · scored 12 Nov
Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.
As of 12 Nov 2026, the MoatMap Score for Stereotaxis, Inc. (STXS) is 7/100, ranked against 25,000+ stocks in 38 markets (Quality 31, Value 25, Momentum 21, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT STEREOTAXIS, INC.
Read
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.1M | 26.8M | 26.9M | 32.4M | 4.8% | 30.1M | 34.3M | 45.7M | 18.8% |
| EPS | -0.26 | -0.27 | -0.30 | -0.25 | — | -0.24 | -0.21 | -0.16 | — |
| Shares | 74.9M | 80.9M | 85.3M | 95.3M | +27.3% | 100.2M | — | — | — |
| Debt | 5.9M | 5.5M | 6.0M | 5.4M | -2.5% | 5.2M | — | — | — |
| Equity | 31.9M | 21.9M | 11.4M | 18.7M | -16.3% | — | — | — | — |
| Op CF | -8.4M | -9.1M | -8.5M | -13.7M | — | -15.3M | — | — | — |
| Inv CF | -22.1M | 19.8M | 74.0K | -93.0K | — | — | — | — | — |
| Fin CF | 0.2M | 81.0K | 0.3M | 14.8M | — | — | — | — | — |
Made a new 52-week low in the latest session, 69% below its 52-week high. The fall has not stopped yet.
Swung more than 71% of stocks we rank over the past year (volatility 57% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STXS are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| STXS | Stereotaxis, Inc.(you) | $102M | 7 |
| KRMD | KORU Medical Systems, Inc. | $146M | 35 |
| DXR | Daxor Corporation | $54M | 36 |
| POCI | Precision Optics Corporation, Inc. | $52M | 35 |
| OSUR | OraSure Technologies, Inc. | $285M | 42 |
| ANGO | AngioDynamics, Inc. | $520M | 35 |
| STAA | STAAR Surgical Company | $1.1B | 33 |
| SMTI | Sanara MedTech Inc. | $301M | 61 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 31 |
| PLSE | Pulse Biosciences, Inc. | $3.8B | 29 |
Peer medians: ROE -30.0% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.